The FDA does not recommend routine calcitonin measurement or thyroid ultrasound screening, as these have uncertain value and are not recommended for patients taking GLP-1 receptor agonists
In summary, this analysis indicated that the cardiorenal benefits of liraglutide and semaglutide were consistent across varying diabetes durations, demonstrating their efficacy in reducing cardiovascular and kidney-related risks in patients with type 2 diabetes
Differential gene expression was assessed by the R package DESeq2
27.2% of participants lost more than 10% of starting weight across three studies
However, if you complete the full 4-6 month treatment, you then qualify for maintenance dosing, which is a pay per vial which would last 2-3 months for maintenance dosing once you achieve your desired weight
This study adheres to the reporting guidelines outlined within the 'Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement